Dr. Sundar Jagannath On Significant Studies In Multiple Myeloma

Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma

Dr. Sundar Jagannath on Three-Drug Regimen for Newly Diagnosed Multiple Myeloma

Dr. Sundar Jagannath Discusses the Approval of Lenalidomide in Multiple Myeloma

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

Dr. Jagannath on Immunotherapy in Multiple Myeloma

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

Dr. Jagannath on Life Expectancy in Multiple Myeloma

Dr. Jagannath on Pomalidomide in Multiple Myeloma

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma

Dr.Jagannath on Role for Two-Drug Combinations, Carfilzomib Triplet in Multiple Myeloma

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

Dr. Jagannath on Targeted Therapies and Stem Cell Transplantation in Multiple Myeloma

Targeted Oncology

Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple Myeloma

Targeted Oncology